AU2017341936B2 - Modular tetravalent bispecific antibody platform - Google Patents

Modular tetravalent bispecific antibody platform Download PDF

Info

Publication number
AU2017341936B2
AU2017341936B2 AU2017341936A AU2017341936A AU2017341936B2 AU 2017341936 B2 AU2017341936 B2 AU 2017341936B2 AU 2017341936 A AU2017341936 A AU 2017341936A AU 2017341936 A AU2017341936 A AU 2017341936A AU 2017341936 B2 AU2017341936 B2 AU 2017341936B2
Authority
AU
Australia
Prior art keywords
amino acid
seq
linker
cdrs
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017341936A
Other languages
English (en)
Other versions
AU2017341936A1 (en
Inventor
Wayne A. Marasco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2017341936A1 publication Critical patent/AU2017341936A1/en
Application granted granted Critical
Publication of AU2017341936B2 publication Critical patent/AU2017341936B2/en
Priority to AU2025200665A priority Critical patent/AU2025200665A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2017341936A 2016-10-14 2017-10-16 Modular tetravalent bispecific antibody platform Active AU2017341936B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025200665A AU2025200665A1 (en) 2016-10-14 2025-01-31 Modular tetravalent bispecific antibody platform

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662408271P 2016-10-14 2016-10-14
US62/408,271 2016-10-14
PCT/US2017/056814 WO2018071913A2 (en) 2016-10-14 2017-10-16 Modular tetrameric bispecific antibody platform

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025200665A Division AU2025200665A1 (en) 2016-10-14 2025-01-31 Modular tetravalent bispecific antibody platform

Publications (2)

Publication Number Publication Date
AU2017341936A1 AU2017341936A1 (en) 2019-04-04
AU2017341936B2 true AU2017341936B2 (en) 2024-10-31

Family

ID=60327374

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017341936A Active AU2017341936B2 (en) 2016-10-14 2017-10-16 Modular tetravalent bispecific antibody platform
AU2025200665A Pending AU2025200665A1 (en) 2016-10-14 2025-01-31 Modular tetravalent bispecific antibody platform

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025200665A Pending AU2025200665A1 (en) 2016-10-14 2025-01-31 Modular tetravalent bispecific antibody platform

Country Status (7)

Country Link
US (1) US20200017588A1 (https=)
EP (1) EP3526257A2 (https=)
JP (3) JP7269167B2 (https=)
CN (2) CN120795163A (https=)
AU (2) AU2017341936B2 (https=)
CA (1) CA3038504A1 (https=)
WO (1) WO2018071913A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019001262A2 (pt) * 2016-07-22 2019-05-07 Dana-Farber Cancer Institute, Inc. anticorpos para o receptor do fator de necrose de tumor induzido por glicocorticoide (gitr) e métodos de uso dos mesmos
EP3576793A4 (en) * 2017-02-06 2021-03-31 Dana Farber Cancer Institute, Inc. COMPOSITIONS AND PROCEDURES FOR ENHANCING ANTIBODY-MEDIATED RECEPTOR SIGNALING
JP7575100B2 (ja) * 2018-11-13 2024-10-29 ジェイエヌ バイオサイエンシーズ エルエルシー 免疫細胞活性化のための二重特異性抗体
JP2022510218A (ja) * 2018-11-30 2022-01-26 メモリアル スローン ケタリング キャンサー センター ヘテロ二量体四価特異性抗体およびこれらの使用
EP4069294A4 (en) * 2019-12-02 2024-07-10 Dana-Farber Cancer Institute, Inc. Antibodies against pd-l1 and methods of use thereof
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
WO2021226984A1 (zh) * 2020-05-15 2021-11-18 三生国健药业（上海）股份有限公司 一种抗pd-1和pd-l1的四价双特异性抗体
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
WO2023034288A1 (en) 2021-08-31 2023-03-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for treatment of autoimmune disorders and cancer
JP2024541476A (ja) 2021-11-24 2024-11-08 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｃｔｌａ－４に対する抗体及びその使用方法
CA3245541A1 (en) 2022-03-09 2023-09-14 Dana-Farber Cancer Institute, Inc. GENETICALLY MODIFIED B LYMPHOCYTES AND ASSOCIATED METHODS OF USE
AU2023324669A1 (en) 2022-08-15 2025-02-13 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
EP4572785A1 (en) 2022-08-15 2025-06-25 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof
AU2024313549A1 (en) * 2023-06-20 2025-10-30 Denali Therapeutics Inc. Dual transporters and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8084026B2 (en) * 2005-01-05 2011-12-27 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
WO2013096346A1 (en) * 2011-12-22 2013-06-27 Development Center For Biotechnology Bispecific t-cell activator antibody
WO2013173820A2 (en) * 2012-05-18 2013-11-21 Scott & White Healthcare Bispecific scfv immunofusion (bif)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE4118120A1 (de) * 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
JP2005518336A (ja) * 2001-06-26 2005-06-23 イムクローン システムズ インコーポレイティド Ｖｅｇｆ受容体に結合する二重特異性抗体
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005060520A2 (en) 2003-11-25 2005-07-07 Dana-Farber Cancer Institute, Inc. ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
EP1695093A1 (en) * 2003-12-05 2006-08-30 multimmune GmbH Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases
WO2006089141A2 (en) 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
US8466263B2 (en) 2005-12-02 2013-06-18 Dana-Farber Cancer Institute, Inc. Carbonic anhydrase IX (G250) anitbodies
RU2010127156A (ru) 2007-12-06 2012-01-20 Дана-Фарбер Кэнсер Инститьют, Инк. (Us) Антитела против вируса гриппа и их применение
WO2009086514A1 (en) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
BRPI0905987A2 (pt) * 2008-02-22 2015-06-30 Dow Global Technologies Inc Sistema de material para armazenamento de energia térmica, método para fabricar um sistema de material para armazenamento de energia térmica e uso de um sistema de material para armazenamento de energia térmica
CA2785907A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
AU2011261396B2 (en) 2010-06-02 2015-11-05 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
EP2543680A1 (en) * 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
US9580509B2 (en) * 2011-11-07 2017-02-28 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
HUE033245T2 (hu) * 2011-12-19 2017-11-28 Synimmune Gmbh Bispecifikus ellenanyag molekula
CN104011080B (zh) * 2011-12-22 2017-10-20 弗·哈夫曼-拉罗切有限公司 用于真核细胞的全长抗体展示系统及其用途
CA2861491C (en) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
EP3511343A1 (en) 2012-05-04 2019-07-17 Dana Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
CA2891764A1 (en) * 2012-11-19 2014-05-22 Baliopharm Ag Recombinant bispecific antibody binding to cd20 and cd95
CN105530959B (zh) * 2013-03-15 2021-09-17 纪念斯隆-凯特琳癌症中心 多聚化技术
MX367668B (es) 2013-03-15 2019-08-30 Dana Farber Cancer Inst Inc Anticuerpos neutralizadores de flavivirus y métodos de uso de los mismos.
EP3594240B1 (en) 2013-05-20 2023-12-06 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies and methods of use
AR097306A1 (es) * 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
KR20160122127A (ko) * 2013-12-23 2016-10-21 자임워크스 인코포레이티드 C-말단의 경쇄 폴리펩타이드 연장부를 포함하는 항체 및 이의 컨쥬게이트 및 이들의 사용방법
EP4043489A1 (en) 2014-03-19 2022-08-17 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
KR20160145813A (ko) 2014-04-25 2016-12-20 다나-파버 캔서 인스티튜트 인크. 중동 호흡기 증후군 코로나바이러스 중화 항체 및 이의 사용 방법
PE20170441A1 (es) * 2014-06-06 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
WO2015197582A1 (en) 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
EP3204418B1 (en) 2014-10-06 2020-03-25 Dana Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
KR102668588B1 (ko) 2015-04-08 2024-05-22 다나-파버 캔서 인스티튜트 인크. 인간화된 인플루엔자 모노클로날 항체 및 그의 사용 방법
CA3119644A1 (en) * 2018-11-30 2020-06-04 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptor factories and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8084026B2 (en) * 2005-01-05 2011-12-27 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
WO2013096346A1 (en) * 2011-12-22 2013-06-27 Development Center For Biotechnology Bispecific t-cell activator antibody
WO2013173820A2 (en) * 2012-05-18 2013-11-21 Scott & White Healthcare Bispecific scfv immunofusion (bif)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MÃ LLER ET AL: "A dimeric bispecific miniantibody combines two specificities with avidity.", FEBS LETTERS, vol. 432, no. 1-2, 1 July 1998 (1998-07-01), pages 45 - 49, XP055058073, ISSN: 0014-5793, DOI: 10.1016/S0014-5793(98)00829-1 *
Pohl, Stefanie Claudia, et al. "A cassette vector system for the rapid cloning and production of bispecific tetravalent antibodies." Antibodies vol 1(1), 2012, pg. 19-38. *

Also Published As

Publication number Publication date
JP2019533675A (ja) 2019-11-21
CN110214152B (zh) 2025-06-13
AU2017341936A1 (en) 2019-04-04
WO2018071913A2 (en) 2018-04-19
CN120795163A (zh) 2025-10-17
JP7269167B2 (ja) 2023-05-08
EP3526257A2 (en) 2019-08-21
CN110214152A (zh) 2019-09-06
US20200017588A1 (en) 2020-01-16
JP7796079B2 (ja) 2026-01-08
AU2025200665A1 (en) 2025-04-10
WO2018071913A3 (en) 2018-05-24
JP2023093642A (ja) 2023-07-04
JP2025142045A (ja) 2025-09-29
CA3038504A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
JP7796079B2 (ja) モジュラー四価二重特異性抗体プラットフォーム
AU2022200257B2 (en) Chimeric antigen receptors and methods of use thereof
AU2019243453B2 (en) Methods of making and using guidance and navigation control proteins
AU2018360800B2 (en) Chimeric antigen receptors specific for B-cell maturation antigen (BCMA)
RU2753902C2 (ru) Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
CN109952112B (zh) Cd123结合蛋白和相关的组合物和方法
CN111954680B (zh) IL2Rβ/共同γ链抗体
KR20230024984A (ko) Cd70-지시 암 면역요법용 유전적으로 변형된 자연 살해 세포
KR20220152316A (ko) 신규한 항-lilrb4 항체 및 유도체 생성물
CN114585645A (zh) 对杂合性丧失作出响应的细胞表面受体
AU2016334623A1 (en) Bispecific antibodies with tetravalency for a costimulatory TNF receptor
KR20230160874A (ko) CD79b, CD20 및 CD3을 표적으로 하는 삼중특이적 항체
CN111971303B (zh) 抗cd27抗体及其用途
CN113423720A (zh) CAR文库和scFv的制造方法
RU2843842C1 (ru) Композиции и способы для лечения egfr-положительных форм рака
RU2824896C2 (ru) Способы получения и применения направляющих и навигационных контрольных белков
KR102960041B1 (ko) Egfr 양성 암을 치료하기 위한 조성물 및 방법
RU2811457C2 (ru) Белки управления, навигации и контроля и способ их получения и применения
CN117460747A (zh) 靶向CD79b、CD20和CD3的三特异性抗体
TW202214846A (zh) 用於治療ｅｇｆｒ陽性癌症之組合物及方法
HK40026017A (en) Methods of making and using guidance and navigation control proteins
HK40026018A (en) Guidance and navigation control proteins and method of making and using thereof
HK40026018B (zh) 制导和导航控制蛋白及其制备和使用方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)